|
Marker Therapeutics, Inc. (MRKR) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Marker Therapeutics, Inc. (MRKR) Bundle
¿Busca evaluar el valor intrínseco de Marker Therapeutics, Inc. (MRKR)? Nuestra calculadora DCF (MRKR) integra datos del mundo real con extensas características de personalización, lo que le permite refinar sus pronósticos y mejorar sus opciones de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | .5 | 1.2 | 9.0 | 3.3 | 5.3 | 8.4 | 13.4 | 21.3 | 33.9 |
| Revenue Growth, % | 0 | 118.95 | 166.01 | 625.17 | -63.23 | 59.19 | 59.19 | 59.19 | 59.19 | 59.19 |
| EBITDA | -22.0 | -27.6 | -36.3 | -19.8 | -11.8 | -5.3 | -8.4 | -13.4 | -21.3 | -33.9 |
| EBITDA, % | -10332.86 | -5919.3 | -2924.62 | -219.79 | -356.14 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .3 | 1.1 | 3.2 | 3.7 | 2.8 | 4.5 | 7.1 | 11.4 | 18.1 | 28.8 |
| Depreciation, % | 134.42 | 230.44 | 254.7 | 40.87 | 84.23 | 85.02 | 85.02 | 85.02 | 85.02 | 85.02 |
| EBIT | -22.3 | -28.7 | -39.5 | -23.5 | -14.6 | -5.3 | -8.4 | -13.4 | -21.3 | -33.9 |
| EBIT, % | -10467.28 | -6149.74 | -3179.32 | -260.66 | -440.37 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 43.9 | 21.4 | 42.4 | 11.8 | 15.1 | 5.3 | 8.4 | 13.4 | 21.3 | 33.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | 1.0 | .0 | 2.4 | 1.0 | 1.9 | 3.1 | 4.9 | 7.8 | 12.5 |
| Account Receivables, % | 26.36 | 214.35 | 0.01908658 | 26.68 | 31.04 | 36.82 | 36.82 | 36.82 | 36.82 | 36.82 |
| Inventories | .0 | -1.0 | .0 | .0 | -1.0 | -1.4 | -2.2 | -3.5 | -5.5 | -8.8 |
| Inventories, % | 0 | -214.23 | 0 | 0 | -29.84 | -25.97 | -25.97 | -25.97 | -25.97 | -25.97 |
| Accounts Payable | 1.0 | 2.9 | 5.1 | 1.1 | 1.0 | 3.6 | 5.7 | 9.1 | 14.5 | 23.1 |
| Accounts Payable, % | 465.77 | 628.77 | 414.27 | 12.23 | 29.02 | 68.25 | 68.25 | 68.25 | 68.25 | 68.25 |
| Capital Expenditure | -.4 | -10.4 | -3.1 | -4.9 | .0 | -3.7 | -6.0 | -9.5 | -15.1 | -24.0 |
| Capital Expenditure, % | -175.89 | -2233.99 | -252.16 | -54.92 | 0 | -70.98 | -70.98 | -70.98 | -70.98 | -70.98 |
| Tax Rate, % | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 |
| EBITAT | -21.2 | -28.5 | -39.5 | -23.5 | -14.6 | -5.2 | -8.3 | -13.2 | -21.0 | -33.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.3 | -35.9 | -37.2 | -31.2 | -9.6 | -2.4 | -5.3 | -8.5 | -13.5 | -21.5 |
| WACC, % | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -33.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -22 | |||||||||
| Terminal Value | -231 | |||||||||
| Present Terminal Value | -134 | |||||||||
| Enterprise Value | -168 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | -153 | |||||||||
| Diluted Shares Outstanding, MM | 9 | |||||||||
| Equity Value Per Share | -17.32 |
What You Will Get
- Real MRKR Financial Data: Pre-filled with Marker Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Marker Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Marker Therapeutics’ historical financial reports and projected forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Marker Therapeutics’ intrinsic value update instantly.
- Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A robust tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Marker Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Marker Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Marker Therapeutics, Inc. (MRKR)?
- Innovative Therapies: Pioneering treatments that utilize cutting-edge technology in immunotherapy.
- Strong Pipeline: A robust portfolio of clinical-stage assets aimed at addressing unmet medical needs.
- Expert Team: Led by seasoned professionals with extensive experience in biopharmaceutical development.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
- Positive Impact: Focused on improving patient outcomes and enhancing the quality of life.
Who Should Use This Product?
- Healthcare Professionals: Understand advanced treatment methodologies and their implications using real-world data.
- Researchers: Integrate cutting-edge models into clinical studies or academic projects.
- Investors: Validate your investment hypotheses and assess valuation scenarios for Marker Therapeutics, Inc. (MRKR).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Biotech Entrepreneurs: Learn from the valuation strategies of established companies like Marker Therapeutics, Inc. (MRKR).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Marker Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Marker Therapeutics, Inc. (MRKR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.